B. Riley lowered the firm’s price target on Novavax (NVAX) to $16 from $18 and keeps a Buy rating on the shares following the Q3 report. The firm highlights the company’s increasingly diversified revenue streams.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVAX:
- Novavax call volume above normal and directionally bullish
- Novavax price target lowered to $16 from $18 at B. Riley
- Novavax’s Strong Financial Outlook and Strategic Partnerships Support Buy Rating
- Novavax Reports Q3 2025 Earnings and Strategic Progress
- Novavax’s Q3 2025 Earnings Call: Optimistic Outlook